Clinical Trials Logo

Clinical Trial Summary

Curative therapy for gastric cancer usually consists of perioperative chemotherapy and a radical (R0) gastrectomy. A radical resection includes a modified D2 lymphadenectomy, and, generally, a complete omentectomy, to ensure the removal of omental metastatic lymph nodes and tumor deposits. The omentum has some essential functions within the peritoneal cavity. The omentum functions as regulator of regional immune responses to prevent infections and, additionally, it prevents adhesions that can lead to small bowel obstruction. Omentectomy is associated with increased incidence of early and late postoperative complications such as abdominal abscess, ileus, and wound infections in various types of surgery. There is little evidence regarding survival benefit of routine complete omentectomy during gastrectomy. The investigators hypothesize that omitting a complete omentectomy (and instead preserve the greater omentum distal of the gastroepiploic arcade) during gastrectomy for cancer does not negatively impact survival. OMEGA is a randomized controlled, open, parallel, non-inferiority, multicenter trial. Adult patients (>18 years) with primary resectable gastric cancer, clinical stage T2-4a N0-3 M0 or cT1N+ scheduled for open or minimally invasive (sub)total gastrectomy are included. The primary study objective is to investigate whether omentum preservation in gastrectomy for cancer is non-inferior to complete omentectomy in terms of three-year overall survival.


Clinical Trial Description

Primary objective: The primary study objective is evaluate whether preservation of the omentum distal to the gastroepiploic vessels in gastrectomy for cancer is non-inferior to complete omentectomy in terms of three-year overall survival. Secondary objectives: Comparing the two study arms with regard to: - Operating time - Intraoperative blood loss - Intraoperative complications - Postoperative complications, defined according to the Clavien-Dindo classification25 and comprehensive complication index (CCI) - Distribution of lymph node metastases - R0-resection rate - Rate of malignant cells in cytology - Molecular sub classification of gastric cancer - ICG fluorescent enhancement of omentum in omentum preservation group (in centers that have ICG fluorescence available) - Protocol compliance to allocated treatment - Hospital stay, defined as time interval between date of surgery and date of hospital discharge - Readmission rate within 30-days after surgery - Reintervention rate within 30-days after surgery - Reoperation rate within three years after surgery - Quality of life at baseline, 3, 6, 9, 12 and 24 months, the following questionnaires will be used: EQ-5D-5L, QLQ-C30, QLQ-OG25, CIPN, Happiness, HADS and work productivity - 3- & 5-year disease-free survival, defined as the period of time from operation to locoregional recurrence, peritoneal recurrence, distant metastases, second gastric cancer or death from any cause. Patients alive and free of all these events will be censored at the last follow-up. - 5-year overall survival, defined as the period of time from operation to death from any cause. Patients alive and free of all these events will be censored at the last follow-up. - Cost-effectiveness Study design: OMEGA is a randomized controlled, open, parallel, non-inferiority, multicenter trial. Eligible patients have to be operable (ASA <4) with resectable (≦cT4aN3bM0) gastric cancer. Patients will be randomized in a 1:1 ratio between radical (sub)total gastrectomy with omentum preservation or complete omentectomy. Patients will be stratified according to center, neoadjuvant therapy and type of surgery (total or subtotal gastrectomy). The primary endpoint is overall survival at three-years after the operation. In total, 654 patients will be randomized. Sample size: The primary endpoint is three-year overall survival. According to survival numbers from the Dutch Cancer Registry (NKR), three-year overall survival after gastrectomy is approximately 50% in the Netherlands. A non-inferiority margin of 5% for three-year overall survival probability is used and under the alternative it is assumed that the experimental group has an enhanced outcome of 5% because of improved early and late morbidity. Under the common assumption of exponential survival times, the hazard ratio under the null hypothesis of non-inferiority is 1.15 and the hazard ratio under the alternative hypothesis equals 0.862. With the minimum follow-up of three years at least 50% and 45% are expected to have an event (i.e. death) in the control arm and experimental arm, respectively. Assuming one-sided testing at a significance level of 5%, 311 patients are needed in each study arm to achieve 80% power (PASS 15 Power Analysis and Sample Size Software (2017). NCSS, LLC. Kaysville, Utah, USA, ncss.com/software/pass). Dropouts will be rare, with proportion dropping out expected to be at most 5%. After correction for drop-out the investigators plan to include 327 patients in each of the two arms (654 in total), requiring an accrual rate of 27 patients per month with an accrual period of two years. All patients will be followed-up until three years after randomization. Statistical analysis: Primary endpoint: Descriptive statistics will be calculated to summarize patients' groups included in each of trial arms. Mean and standard deviation will be presented for normally distributed continuous variables. Median plus interquartile-range (IQR) will be presented continuous variables that are skewed and for ordinal variables. Dichotomous and nominal data will be summarized by means of frequencies and percentages. Non-inferiority of the experimental treatment in terms of overall survival will be tested using Cox-regression. Non-inferiority will be concluded if the upper limit of the 90% confidence interval falls below the non-inferiority hazard ratio of 1.15, corresponding to a one-sided non-inferiority test at significance level of 5%. Survival will be presented graphically using Kaplan-Meier curves. All analyses will be according to the intention to treat principle. A per protocol analysis will also be performed. The experimental treatment will be declared non-inferior if non-inferiority is shown in both the intention to treat and the per protocol analysis. Secondary endpoint: as independent samples t-test for normally-distributed continuous outcomes, Mann-Whitney tests for continuous outcomes that are not normally distributed or ordinal outcomes. Categorical outcomes will be compared using chi-square test or Fisher's exact test in case of low (expected) cell counts. Repeatedly measured outcomes will be compared between arms using linear mixed models. Secondary time-to-event outcomes will be compared the using log-rank test. Secondary endpoints will be tested at a two-sided significance level of 5%. Effect sizes suitable for the type of outcome measure will be provided (mean differences, ratio of geometric means, relative risks, hazard ratios) together with their 95% confidence interval. Subgroup analysis for the effect of experimental treatment on overall survival will be performed for the follow subgroups: patient characteristics (age, male/female), diffuse/intestinal type gastric tumor, subtotal/total gastrectomy, and minimally invasive/open gastrectomy. Effect modification will use Cox regression with the subgroup variable, the arm and their two-way interaction. Additionally, stratified analyses will be performed where HR is calculated separately in each of the subgroups. Quality of life data will be graphically represented across all time points and analyzed according to the manuals and will presented as domain and summarized scores. Questionnaire outcome comparisons will be analyzed using linear mixed models. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05180864
Study type Interventional
Source VU University of Amsterdam
Contact Suzanne S. Gisbertz, MD, PhD
Phone 0031204444444
Email [email protected]
Status Not yet recruiting
Phase N/A
Start date November 2022
Completion date December 2027

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03313700 - Clinical Outcomes of Robotic Versus Laparoscopic Distal Gastrectomy for Gastric Cancer N/A
Recruiting NCT03549494 - Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction Phase 2
Completed NCT00935779 - Ultra Structure Of Peritoneum At Electronic Microscopy In Control Subjects And Patients With Gastric Cancer N/A
Completed NCT00144378 - Irinotecan Versus Only Best Supportive Care for Gastric Cancer Phase 3
Completed NCT00290966 - Randomized Multicenter Study Comparing Docetaxel Plus Cisplatin and 5-FU to Cisplatin Plus 5-FU in Advanced Gastric Cancer Phase 2/Phase 3
Recruiting NCT03348150 - Gastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer With Peritoneal Dissemination. Phase 3
Recruiting NCT02969122 - Treatment Strategy for Stage IV Gastric Cancer With Positive Peritoneal Cytology as the Only Non-curable Factor N/A
Completed NCT01482299 - RAD001 in Advanced Gastric Cancer Who Failed Standard First-line Treatment With pS6 Ser 240/4 Expression Phase 2
Active, not recruiting NCT03153280 - Dose Escalation Study of Lithium With Oxaliplatin and Capecitabine in Advanced Oesophago-Gastric or Colorectal Cancer Phase 1
Recruiting NCT03760822 - Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients Phase 2
Recruiting NCT00509964 - Second-Line Irinotecan vs. ILF for AGC Phase 2
Recruiting NCT04889859 - Impact of Biliopancreatic Limb Length on Diabetes Following Distal Gastrectomy N/A
Completed NCT03071237 - The Origin of Infrapyloric Artery
Completed NCT00142038 - Docetaxel and Capecitabine in Advanced Gastric Cancer Phase 2
Not yet recruiting NCT04056260 - ICG-NIR Guided Lymph Node Dissection in Gastric Cancer N/A
Recruiting NCT03065257 - Endoscopic Resection Multicenter Registry N/A
Recruiting NCT04744649 - Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial Phase 2
Recruiting NCT05007912 - Prospective Observational Study Comparing the Use of Circular (Orvil) and Linear Stapler for Intracorporeal Esophagojejunostomy
Not yet recruiting NCT04893252 - Vactosertib and Durvalumab in Gastric Cancer Phase 2
Recruiting NCT03524300 - Clinical Efficacy Between Robotic and Laparoscopic Total Gastrectomy in Patients With Clinical Stage I Gastric Cancer N/A